Swiss Auto Components Stock News

SWX:SOON
SWX:SOONMedical Equipment

Sonova Holding (SWX:SOON) Is Up 9.8% After Record Dividend And Strong Normalized EBITA Growth - What's Changed

Sonova Holding AG has released its full-year results for the period ended March 31, 2026, reporting sales of CHF 3,605.9 million, net income of CHF 430.6 million, and announcing an annual dividend of CHF 4.70 per share payable on June 23, 2026. Despite lower reported net income year-on-year, the company achieved 5.9% sales growth and a 17.3% increase in normalized EBITA in local currencies, primarily driven by its Hearing Instruments segment and supported by business reshaping and the...
SWX:CMBN
SWX:CMBNConsumer Finance

European Dividend Stocks To Consider For Income

As European markets navigate the challenges of geopolitical tensions and inflationary pressures, investors continue to seek stability and growth through dividend stocks. In such a climate, selecting stocks with robust earnings growth and consistent dividend payouts can be an effective strategy for those looking to generate income while potentially mitigating volatility.
SWX:AMS
SWX:AMSSemiconductor

A Look At Ams-OSRAM (SWX:AMS) Valuation After Q1 2026 Earnings And Softer Revenue Guidance

ams-OSRAM (SWX:AMS) drew fresh attention after reporting first quarter 2026 results that showed lower sales and a wider net loss, alongside new guidance indicating slightly softer full-year revenue due to divestments and currency effects. See our latest analysis for ams-OSRAM. The Q1 results and softer full year guidance came after a sharp rebound in the stock, with a 30 day share price return of 50.80% and a 90 day share price return of 119.51%. However, the 3 year total shareholder return...
SWX:NOVN
SWX:NOVNPharmaceuticals

Assessing Novartis (SWX:NOVN) Valuation After Promising Pluvicto Prostate Cancer Data

Novartis (SWX:NOVN) is back in focus after new clinical data showed its radioligand therapy Pluvicto, when added to standard treatment, cut the risk of PSA progression by 58% in a specific prostate cancer setting. See our latest analysis for Novartis. Alongside the Pluvicto data and a series of US manufacturing and research expansions, Novartis has seen firm investor interest, with the share price at CHF117.2 and an 8.02% year to date share price return, while the 1 year total shareholder...
SWX:SCMN
SWX:SCMNTelecom

Is It Too Late To Consider Swisscom (SWX:SCMN) After A 27% One-Year Rally?

Investors may be asking whether Swisscom at CHF676.0 is offering fair value right now, or if the recent momentum has already priced in the opportunity. The stock has returned 1.0% over the past week, 3.9% over the past month, 16.8% year to date, and 27.2% over the last year, which naturally raises questions about how much of its potential is already reflected in the price. Recent attention on Swisscom has focused on its role as a major Swiss telecom operator and how investors view its...
SWX:ADEN
SWX:ADENProfessional Services

Assessing Adecco Group (SWX:ADEN) Valuation After Q1 2026 Earnings And AI Productivity Push

Q1 earnings spark fresh look at Adecco Group stock Adecco Group (SWX:ADEN) just released Q1 2026 results, with organic revenue growth, higher net income and EBITA, and market share gains in the Americas and APAC putting the stock back in focus. See our latest analysis for Adecco Group. Despite the Q1 2026 earnings lift, the share price has fallen 36.36% year to date, contributing to a 33.17% decline in 1 year total shareholder return and signalling fading momentum despite improving...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is Novartis’ US Radioligand Manufacturing Buildout (SWX:NOVN) Altering Its Investment Case?

In early May 2026, Novartis broke ground on a new 46,000 sq. ft radioligand therapy manufacturing facility in Denton, Texas, part of its US$23.00 billion US manufacturing and research expansion and its fifth radioligand therapy site nationwide. This build-out of a coast-to-coast radioligand therapy network highlights how Novartis is tying manufacturing proximity and reliability directly to complex cancer treatment delivery for US patients. We will now explore how this expanded US radioligand...
SWX:LAND
SWX:LANDElectronic

Landis+Gyr Group (SWX:LAND) Valuation Check After Annual Loss And Weak Long Term Returns

Landis+Gyr Group (SWX:LAND) has recently drawn attention after its latest financial data showed annual revenue of $1,625.8m and a net loss of $136.1m, prompting investors to reassess the smart metering specialist. See our latest analysis for Landis+Gyr Group. At a share price of CHF47.85, Landis+Gyr Group has seen short term share price momentum pick up, with a 7 day share price return of 6.93%. However, longer term total shareholder returns over 3 and 5 years remain weak and suggest...
SWX:TEMN
SWX:TEMNSoftware

Assessing Temenos (SWX:TEMN) Valuation After New Banking Deals And AI Product Launches

Temenos (SWX:TEMN) is back in focus after a cluster of fresh contracts and product launches, including new core banking deals with Habib Bank Limited and Reliance Bank, as well as extended collaborations with First Abu Dhabi Bank and Questrade Financial Group. See our latest analysis for Temenos. The recent stream of banking deals and AI product launches comes against a mixed backdrop. The share price stands at CHF71.45, with a 90 day share price return of 11.29%, but a year to date share...
SWX:ADEN
SWX:ADENProfessional Services

Adecco Group (SWX:ADEN) Margin Stagnation Challenges Bullish Profit Expansion Narrative

Adecco Group (SWX:ADEN) opened 2026 with Q1 revenue of €5.7b and basic EPS of €0.41, setting a clear benchmark for how the year is starting after a steady run of quarterly results. The company has seen revenue move from €5.6b in Q1 2025 to €5.7b in Q1 2026, while basic EPS over that same period went from €0.36 to €0.41. Trailing twelve month EPS of €1.81 provides a broader earnings backdrop. With net income of €69m in the quarter and a net profit margin of 1.3%, the story now is how...
SWX:ADEN
SWX:ADENProfessional Services

Akkodis AI Recognition Puts Focus On Adecco Group Valuation Gap

Akkodis, a subsidiary of Adecco Group (SWX:ADEN), has been recognized as an Enterprise Innovator for its agentic AI capabilities. The recognition highlights Akkodis' progress in practical AI deployment and Services-as-Software transformation across enterprise clients. The assessment emphasizes strengths in scalable AI execution and data governance, pointing to operational impact beyond financial metrics. Adecco Group, through Akkodis, is leaning into AI driven services at a time when large...
SWX:UBSG
SWX:UBSGCapital Markets

A Look At UBS Group (SWX:UBSG) Valuation After Recent Share Price Momentum And Mixed Analyst Targets

Recent performance snapshot UBS Group (SWX:UBSG) has drawn investor attention after a recent move in the share price, with the stock last closing at CHF 36.22. That puts its market value around CHF 106b. Over the past month, the stock has returned 9.6%, and over the past 3 months it has returned 12.4%. The 1 year total return stands at 35.0%, with a 3 year total return a little over 12x and a 5 year total return almost 20x. See our latest analysis for UBS Group. The recent 1 day share price...
SWX:PSPN
SWX:PSPNReal Estate

PSP Swiss Property (SWX:PSPN) One Off Gain Tests Quality Premium Heading Into Q1 2026

PSP Swiss Property (SWX:PSPN) has opened Q1 2026 earnings season with trailing 12 month revenue of CHF 351.05 million and Basic EPS of CHF 8.91, backed by an 8.9% year over year improvement in earnings and supported by a one off gain of CHF 238.8 million that lifted reported profit. Over recent quarters, revenue has held in a tight band between CHF 87.44 million and CHF 88.65 million per quarter, while quarterly Basic EPS has ranged from CHF 1.32 to CHF 3.25. This has fed into that CHF 8.91...
SWX:SREN
SWX:SRENInsurance

Swiss Re (SWX:SREN) Valuation Check After Q1 2026 Earnings And Recent Share Price Weakness

Q1 earnings set the tone for Swiss Re stock Swiss Re (SWX:SREN) put its first quarter on the table on May 7, reporting net income of US$1,506 million versus US$1,267 million a year earlier, alongside its Q1 2026 earnings call. See our latest analysis for Swiss Re. Despite the stronger Q1 net income, the stock has come under pressure, with the share price down 10.6% over the past month and the 1 year total shareholder return declining 14.08%, although the 5 year total shareholder return of...
SWX:SENS
SWX:SENSElectronic

Sensirion Holding (SWX:SENS) Is Up 5.5% After Debt-Free 18.6% Revenue Growth Reported

Earlier this week, Sensirion Holding reported revenue growth of 18.58% alongside a zero-debt balance sheet and solid liquidity, reinforcing its financial strength. This combination of accelerating top-line performance and a clean capital structure adds an extra layer of resilience to Sensirion’s existing growth story. Next, we’ll examine how this strong revenue momentum and debt-free position may reshape Sensirion Holding’s existing investment narrative. Capitalize on the AI...
SWX:HBAN
SWX:HBANInsurance

European Stocks Estimated To Be Up To 30.8% Below Their Intrinsic Value

The European stock market recently experienced a volatile week, with modest gains in the pan-European STOXX Europe 600 Index, as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings. However, looming threats of increased tariffs from the U.S. added pressure to markets. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities that are potentially trading below their intrinsic value amidst fluctuating market...
SWX:VATN
SWX:VATNBanks

Valiant Holding (SWX:VATN) Is Down 8.4% After Mixed Q1 Results Trigger A Rethink On Fair Value

Valiant Holding AG reported first-quarter 2026 results with net interest income of CHF 100.64 million and net income of CHF 33.24 million, both slightly higher than a year earlier. Despite this modest improvement, investors focused on the bank’s challenging revenue trends. We’ll now examine how these weaker-than-expected earnings in the context of the bank's valuation estimates.
SWX:KURN
SWX:KURNBiotechs

Assessing Kuros Biosciences (SWX:KURN) Valuation After Recent Share Price Weakness

Why Kuros Biosciences (SWX:KURN) is on investors’ radar today Kuros Biosciences (SWX:KURN) has drawn attention after recent share price pressure, with the stock showing a 15.1% decline over the past month and a 20.2% decline over the past 3 months. See our latest analysis for Kuros Biosciences. At the latest share price of CHF20.12, Kuros Biosciences shows weaker short term momentum, with a 1 month share price return of 15.1% decline and a year to date share price return of 24.6% decline,...